Chair Rodgers Opening Statement at Hearing with FDA Center Directors

Energy & Commerce GOP
48 followers
May 22, 2024
The Committee on Energy and Commerce is the oldest standing legislative committee (established 1795) in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee. The Energy and Commerce Committee is at the forefront of all issues and policies powering America’s economy, including our global competitive edge in energy, technology, and health care. The committee is led by E&C Chair Cathy McMorris Rodgers (R-WA) and E&C Ranking Member Frank Pallone (D-NJ).
E&C Website: https://energycommerce.house.gov
E&C Twitter: https://twitter.com/HouseCommerce
E&C Facebook: https://www.facebook.com/energyandcommerce/
E&C Instagram: https://www.instagram.com/energyandcommerce/
thank you the gentle lady yields back
and the chair recognizes chair Rogers
for five minutes for her opening
statement thank you chairman Guthrie Dr
cavazoni Dr Marx Dr shuran thank you for
joining us today the FDA plays a
critical role in the health and
well-being of the American people it is
if it is successful in its Mission it
has the potential to save and extend
people's lives if it fails in his
mission the cost could be astronomical
and devastating the fda's responsib for
regulating more than $3.6 trillion doar
worth of food tobacco and medical
products about 20 cents of every dollar
spent in the United States Americans
must have confidence that the agency is
doing its job they have to be able to
trust that medical products they are
relying on are safe and effective and it
is congress's duty to ensure that the
FDA is using the resources and
authorities it has been given to protect
and Advance public health I'm proud that
America has been a leader in developing
Innovative treatments such as
non-addictive Med medicines for chronic
pain so-called n of one drugs where
hospitals are making drugs designed for
one patient and implantable upper Airway
devices for Pediatric patients with Down
syndrome and severe sleep apnea all
these things which will make meaningful
difference in people's lives were
recently approved by the FDA or will be
seeking review in the near future
there are also advances that could
reduce the amount of time it takes for
new technology to reach patients in need
new biomarkers have been developed from
advances in genetic sequencing
manufacturing techniques and methods to
generate clinical data that if used
properly could decrease cost and time to
demonstrate these new technologies meet
FDA
standards this committee worked in a
bipartisan manner to give FDA new tools
in the last user fee reauthorization and
we expect the agency to use these tools
to pave the way for groundbreaking
Innovation I firmly believe that the
accelerated approval pathway should be
leveraged now more than ever as more and
more diseases can be treated or even
cured because of a better understanding
of their mechanisms of action and
genetic signatures FDA approval
unfortunately is not the final hurdle
for patients as significant problems
with CMS and private coverage still
persist but it is an important First
Step FDA cannot move backwards and I'm
wor worried that we're starting to see
warning signs that that may be occurring
for example I'm disappointed to see that
according to the fiscal year 2023 PFA
and MFA performance reports all three
centers here before us today have failed
to meet critical performance process and
hiring goals despite all-time highs in
funding in addition the agency has been
failing to add adequately accommodate
in-person meetings and to respond to
outreach related to Major clinical and
scientific development decisions in a
timely manner this is especially
concerning as the FDA has unilaterally
decided it can regulate by its own
estimate 80,000 test under the
laboratory developed test final rule FDA
leadership often says that the right
right says the right things regarding
speeding up Innovation to patients when
the benefits outweigh the risk such as
not asking nice to know questions if the
statutory standard for approval has been
met not moving the goal poost after a
company has invested millions of dollars
in years of time on a clinical trial FDA
once said was the best best path forward
the challenge is making sure the
sentiments expressed by the agency's
leadership are reflected by the
application reviewers unfortunately I'm
hearing the opposite from stakeholders
who are finding FDA review staff more
disconnect Ed and difficult to work with
than ever before everyone on this dis
wants the FDA to succeed because if the
FDA succeeds American innovation
flourishes leading to better outcome for
patients and I'm hopeful that we can
have a productive conversation about
what challenges the agency is facing and
why and how Congress can help the FDA
streamline operations and provide clear
consistent scientific and regulatory
information to innovators and Drug
manufacturers that are looking to
improve the daily lives of Americans
thank you and I yield back G lady yields
back and the chair recogniz a ranking
member of the full committee
